Baker McKenzie has advised Biocartis Group NV and its group companies on the enforcement by Biocartis’s secured credtiors. As a result of the process used, the enforcement is not expected to impact Biocartis’s customers, suppliers, partners or employees, allowing it to continue its innovative work in molecular diagnostics.
Baker McKenzie has represented Biocartis from VC-stage through to its 2015 IPO on Brussels Euronext, multiple rounds of convertible bond and debt financing as well as rights offerings, and ultimately a well-managed collateral enforcement against the assets by the secured lenders – a testimony to our high-value cross-practice group, cross-office collaboration.
The Brussels and London based cross-border team, led by Adam Farlow, Michael Van Acker, Roel Meers and Luc Meeus, also included Joren Jansseune, Arne Naert and Max Khrapov, and additional team members in Italy, Hong Kong and North America.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
